The use of different prognostic systems applied to myelodysplastic syndromes: A retrospective analysis

DEMİRKAN F., ÇABUK M., ÖZSAN G. H., Pehlivan M., Yuksel E., ÖZTOP İ., ...Daha Fazla

Turkish Journal of Haematology, cilt.17, sa.3, ss.101-109, 2000 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 3
  • Basım Tarihi: 2000
  • Dergi Adı: Turkish Journal of Haematology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.101-109
  • Anahtar Kelimeler: Cytogenetics, Myelodysplastic syndromes, Prognostic systems
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Sixty-nine patients with myelodysplastic syndromes (MDS) were followed at Dokuz Eylul University Medical School between 1990 and 1999 and have been reviewed retrospectively to compare the various prognostic systems. All patients were scored according to the French-American-British (FAB) Cooperative Group and the Bournemouth Scoring System, and patients with available cytogenetic results (44 patients) were also scored according to the International Prognostic Scoring System (IPSS). The median survival rate of patients was 33.6 ± 9.8 months. Both the Bournemouth and the IPSS groups correlated with the FAB subgroups in terms of median survival and 1 year survival rates. The estimated median overall survival rate (OS) was 43.7, 11.2 ± 3.0, 19.6 ± 10.5 months and 1 year OS was 88%, 43.5%, 55% for refractory anemia + refractory anemia with ring sideroblasts (RA+RARS), refractory anemia with excess of blasts+refractory anemia with excess of blasts in transformation (RAEB + RAEB-t) and CMML groups, respectively. Advanced investigational methods in cytogenetics might improve the sensitivity of the IPSS and identify the heterogeneous groups, especially in RA and RARS.